1 / 22

Leprosy (Hansen’s Disease)

Leprosy (Hansen’s Disease). Amanda Lee BIOL 402. Leprosy is caused by Mycobacterium leprae. Scollard, DM et al. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81. Discovered by Gerhard Armauer Hansen in 1873.

anne-cash
Télécharger la présentation

Leprosy (Hansen’s Disease)

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Leprosy (Hansen’s Disease) Amanda Lee BIOL 402

  2. Leprosy is caused by Mycobacterium leprae Scollard, DM et al. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81.

  3. Discovered by Gerhard Armauer Hansen in 1873 Global Project on the History of Leprosy http://www.leprosyhistory.org/graphics/gallery/hansen.jpg

  4. Bacteria Resides in Cooler Parts of the Body Peripheral Nerves Skin http://www.nlm.nih.gov

  5. Symptoms & Diagnosis: (1) Skin Lesions Worobec, Sophie M. 2009. “Treatment of leprosy/Hansen's disease in the early 21st century.” Dermatologic therapy 22, no. 6: 518-37.

  6. Symptoms & Diagnosis: (2) Skin Smear Tests Ziehl Neelsen Carbol Fuchsin Stain (ZNCF) Global Project on the History of Leprosy http://www.leprosyhistory.org/graphics/gallery/mleprae.jpg

  7. Transmission • Nasal/oral Droplets • Dermal Inoculations

  8. Immunocompromised individuals are more susceptible to disease

  9. Mechanism of Nerve Damage • Entry Through Blood Vessels 2. Inflammatory Response 3. Demyelination Scollard, DM et al. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81.

  10. Outcomes of Nerve Damage • Sensory Loss • Paralysis • Deformities Leprosy: eMedicine Infectious Diseases http://emedicine.medscape.com/article/220455-overview

  11. Sensory Loss Can Lead to Secondary Infections and Severe Deformities International Federation of Anti-Leprosy Associations (ILEP) http://www.ilep.org.uk/en/

  12. 1941: Discovery of Dapsone • Targets dihydropteroate synthase (DHPS) • Inhibits nucleic acid synthesis

  13. 1964: Dapsone Resistance from Missense Mutations in DHPS Matsuoka, Masanori M. 2010. “Drug Resistance in Leprosy.” Japanese journal of infectious diseases 63, no. 1: 1-7.

  14. 1960’s: Rifampicin and Clofazimine Discovered • Rifampicin (Rifampin): Inhibit RNA synthesis • Clofazimine: Anti-inflammatory

  15. 1981: WHO Proposes Multi-Drug Therapy (MDT) • Combination of DAPSONE, RIFAMPICIN, and CLOFAZIMINE + +

  16. The Nippon Foundation http://www.nippon-foundation.or.jp/eng/

  17. 1995: WHO Distributes MDT Drugs for Free to Worldwide Patients

  18. 1999: Global Alliance to Eliminate Leprosy As a Public Health Problem

  19. Obstacles to Eliminating Leprosy in Endemic Countries STIGMA World Health Organization. 2001. “Leprosy: Learning from Success.” WHO Publications on Leprosy.

  20. Overcoming Stigma • Mass Media • Integrated Primary Health Services • Education & Training

  21. Worobec, Sophie M. 2009. “Treatment of leprosy/Hansen's disease in the early 21st century.” Dermatologic therapy 22, no. 6: 518-37.

  22. References • Leprosy Today. “Leprosy: The Disease.” World Health Organization. http://www.who.int/lep/leprosy/en/index.html (accessed February 25 2010). • Matsuoka, Masanori M. 2010. “Drug Resistance in Leprosy.” Japanese journal of infectious diseases 63, no. 1: 1-7. http://www.nih.go.jp.libproxy.lib.unc.edu (accessed February 25, 2010). • National Hansen’s Disease (Leprosy) Program. “Hansen’s Disease (Leprosy) Facts.” U.S. Department of Health and Human Services. http://www.hrsa.gov/hansens/ Accessed February 25 2010. • Scollard, DM, LB Adams, TP Gillis, JL Krahenbuhl , RW Truman, and DL Williams. 2006. “The continuing challenges of leprosy.” Clinical microbiology reviews 19, no. 2: 338-81. http://www.ncbi.nlm.nih.gov.libproxy.lib.unc.edu (accessed February 25, 2010). • Worobec, Sophie M. 2009. “Treatment of leprosy/Hansen's disease in the early 21st century.” Dermatologic therapy 22, no. 6: 518-37.http://www3.interscience.wiley.com.libproxy.lib.unc.edu(accessed February 25, 2010.

More Related